Skip to content
    Guidelines & Consensus

    Cardio-Oncology in Older Adults: Addressing Evidence Gaps, Frailty, and Geriatric Considerations

    Katsi et alJournal of Clinical Medicine

    Cardio-oncology addresses cardiovascular toxicities secondary to cancer therapies, yet critical evidence gaps persist for older adults, who account for over 60% of all new cancer diagnoses. Elderly patients (defined as those aged 65 years and older) remain significantly underrepresented in clinical trials, resulting in a shortage of geriatric-specific guidelines, validated monitoring algorithms, and management thresholds. Age-related physiological changes—specifically reduced cardiac reserve, impaired renal function, and pre-existing subclinical or clinical atherosclerosis—substantially increase vulnerability to antineoplastic cardiotoxicity, a risk compounded by frailty, multimorbidity, and polypharmacy.
    Comprehensive geriatric assessment (CGA) serves as an essential risk-stratification approach by identifying frailty as a key predictor of adverse clinical outcomes, although its routine integration into cardio-oncology pathways remains inconsistent. Observational studies demonstrate widespread disparities in surveillance and management, which frequently culminate in clinical missteps such as the undertreatment of underlying malignancies and the overtreatment of co-existing medical comorbidities. While current cardio-oncology guidelines acknowledge age, frailty, and multimorbidity in decision-making, prospective evidence regarding specific biomarkers and imaging thresholds remains limited, particularly for frail individuals and the oldest-old population. To bridge these evidence gaps, multidisciplinary care models incorporating geriatricians and age- and frailty-stratified frameworks are needed to optimize shared decision-making, improve care equity, and tailor cardiovascular risk assessment in elderly cancer patients.

    Key Takeaways

    • Patients aged 65 years and older account for over 60% of new cancer diagnoses and face elevated susceptibility to antineoplastic cardiotoxicity driven by age-related declines in cardiac reserve and renal function alongside baseline atherosclerosis.
    • Comprehensive geriatric assessment identifies frailty as a critical predictor of adverse clinical outcomes in older adults undergoing cancer therapy.
    • Observational data indicate that disparities in cardio-oncology surveillance and management lead to both the undertreatment of malignancies and the overtreatment of comorbidities in older patients.
    Read the original sourceJournal of Clinical Medicine